盤後交易 18:30 (美東)46.010USD+0.160+0.35%關鍵數據
44.190今開
44.650最高
281.23K成交量
49.40本益比TTM
72.83本益比動
--股利TTM
0.17%換手率
44.540昨收
44.070最低
12.77M成交額
20.99本益比靜
4.13市淨率
0.00%股息率 TTM
4.82%ROA
55.67052週最高
59.54量比
367.07M淨利潤
167.76M總股本
0.9298每股盈餘TTM
0.31Beta
9.36%ROE
27.00052週最低
5.56%振幅
77.51%毛利率
7.70B總市值
-2.28回報/風險
2.55%風險率

即將為您帶來更多新聞,敬請期待。 。 。
Alkermes Plc評分
0.03與上次評分對比預測7.70
財務診斷8.22
技術分析4.29
公司估值8.77
機構認同度10.00
風險評估7.49
分析師評級
買入評級
56.259目標均價
+24.08%漲幅空間
Alkermes Plc 最新財報電話會記錄
Alkermes (ALKS) 2026 年第三季財報電話會議:營收 4.801 億美元與食慾素催化劑
Alkermes 2026 年第三季營收達到 4.801 億美元,主因自營產品銷售額成長 31%。管理層維持財測指引,並概述即將公布的六項食慾素(orexin)臨床數據結果。
財務指標
貨幣: USD

由於公司未披露,未能獲取相關數據
貨幣: USD

由於公司未披露,未能獲取相關數據
Alkermes Plc 簡介
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
行業生物技術與醫療研究
公司代碼ALKS
員工數量1800
國家Ireland
持股情況
| 持股股東 | 佔比 |
|---|
| BlackRock Institutional Trust Company, N.A. | 14.44% |
|---|
| Baker Bros. Advisors LP | 6.01% |
|---|
| Vanguard Portfolio Management, LLC | 5.71% |
|---|
| State Street Investment Management (US) | 5.68% |
|---|
| 股東類型 | 佔比 |
|---|
| Investment Advisor | 53.46% |
|---|
| Investment Advisor/Hedge Fund | 29.75% |
|---|
| Hedge Fund | 19.22% |
|---|
| Research Firm | 2.48% |
|---|
常見問題
Alkermes Plc(ALKS)的當前股價是多少?
Alkermes Plc(ALKS)的當前股價是 45.90。
Alkermes Plc股票的52週最高點是多少?
Alkermes Plc股票的52週最高點是55.67。
Alkermes Plc股票的52週最低點是多少?
Alkermes Plc股票的52週最低點是27.00。
現在Alkermes Plc(ALKS)的股票是買入、持有還是賣出?
根據分析師評級,Alkermes Plc(ALKS)的總體評級為買入,目標價格為56.26。
Alkermes Plc(ALKS)股票的每股收益(EPS TTM)是多少
Alkermes Plc(ALKS)股票的每股收益(EPS TTM)是0.93。